CytomX Therapeutics, Inc. (CTMX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 69
- Market Cap
- $714M
About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
SentiSense also tracks daily options readings for CytomX Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
CytomX Therapeutics, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.